心通医疗-B(02160)发盈警 预期上半年净亏损约5000万-6500万元 同比减少约63%-72%
心通医疗-B(02160)公布，该集团预期2024年上半年取得净亏损约人民币5000万-6500万元，同比减少约63%至 72%。
公告称，该等净亏损减少主要是由于：经导管主动脉瓣植入术(TAVI)产品在全球商业化方面的持续推进，以及AnchorMan®左心耳封堵器系统及其导引系统在中国的商业化进展，共同推动收入较上年同期增长约22%至28%; 集团产品销售量增长带来的规模效应，以及公司对供应链的持续优化，推动生产成本进一步降低，毛利率较上年同期提升超过四个百分点;及集团通过统筹内外部资源、发挥集约效应、提升运营效率等措施，实现了业务的健康可持续增长。
未来，集团将进一步丰富产品组合，积极拓宽收入渠道，力争实现2025年扭亏为盈。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.